ALIM - アリメラ・サイエンシ―ズ （Alimera Sciences Inc.） アリメラ・サイエンシ―ズALIMのチャート
ALIMの企業情報
| symbol | ALIM |
|---|---|
| 会社名 | Alimera Sciences Inc. （アリメラ・サイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アリメラ・サイエンシーズ(Alimera Sciences Inc.)は処方眼科医薬品の研究・開発・商業化を専門に扱うバイオ医薬品企業。同社は眼底や網膜に影響を与える疾患を中心に取り扱う。同社の製品候補「ILUVIEN」は非外科的治療手順であり、25ゲージ針付きのデバイスを採用し、傷のセルフシールを可能にする。また、「ILUVIEN」はドライ型加齢黄斑変性症（AMD）、ウェット型AMD及び網膜静脈閉塞症（RVO）を治療するために３つの第２相臨床試験で研究されている。「ILUVIEN」は硝子体内インプラントであり、非独占の副腎皮質ステロイドであるフルオシノロンアセトニド（FAc）の持続的なサブマイクログラムレベルを提供することにより、糖尿病性黄斑浮腫（DME）に関連する視力障害の治療で最大36ヶ月の治療効果を提供する。 アリメラ・サイエンシ―ズは米国のバイオ医薬品メ―カ―。眼科薬の研究、開発、商業化に従事。主に、眼球の裏側や網膜に影響を及ぼす疾患に焦点を当てている。慢性糖尿病性黄斑浮腫に関連した視力障害治療薬「イルビエン」は、英国、オ―ストリア、ポルトガル、フランス、ドイツ、スペインで販売承認を受けている。本社はジョ―ジア州。 Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. |
| 本社所在地 | 6120 Windward Parkway Suite 290 Alpharetta GA 30005 USA |
| 代表者氏名 | Richard S. Eiswirth リチャードエスワース |
| 代表者役職名 | President Chief Financial Officer |
| 電話番号 | +1 678-990-5740 |
| 設立年月日 | 37773 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 126人 |
| url | www.alimerasciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alim |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.46000 |
| 終値（lastsale） | 0.931 |
| 時価総額（marketcap） | 65205760.641 |
| 時価総額 | 時価総額（百万ドル） 66.07424 |
| 売上高 | 売上高（百万ドル） 39.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 156.19224 |
| 当期純利益 | 当期純利益（百万ドル） -24.19300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alimera Sciences Inc revenues increased 22% to $20.7M. Net loss increased 23% to $11.7M. Revenues reflect United States segment increase of 20% to $15M International segment increase of 28% to $5.7M. Higher net loss reflects United States segment loss increase of 21% to $2.7M International segment loss increase of 27% to $1.2M. |
ALIMのテクニカル分析
ALIMのニュース
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript 2022/02/24 16:59:06 Seeking Alpha
Alimera Sciences GAAP EPS of -$0.59 misses by $0.17, revenue of $13.95M beats by $0.55M 2022/02/24 13:05:37 Seeking Alpha
Alimera Sciences press release (ALIM): Q4 GAAP EPS of -$0.59 misses by $0.17.Revenue of $13.95M (+1.3% Y/Y) beats by $0.55M.
Alimera Sciences Reports Fourth Quarter and FY 2021 Results 2022/02/24 13:00:00 GlobeNewswire
Fourth Quarter Highlights:
Alimera Sciences Q4 2021 Earnings Preview (NASDAQ:ALIM) 2022/02/23 16:11:57 Seeking Alpha
Alimera Sciences (NASDAQ:ALIM) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.28 and the consensus
Alimera''s 3-year data for ILUVIEN shows benefit in diabetic macular edema 2022/02/23 14:48:57 Seeking Alpha
Alimera Sciences (ALIM) reported three-year results of a study, called PALADIN, of the ILUVIEN implant in patients with diabetic macular edema ((DME)), an eye complication in people
Alimera Sciences will move its headquarters into the latest phase of a 135-acre Alpharetta project 2021/06/02 12:03:07 BusinessMag
Alimera maintains its headquarters in a 2-story building at 6120 Windward Parkway that was developed over 20 years ago.
Alimera Sciences, Inc. to Present at the Summer Solstice Best Ideas from the Buy Side Conference on June 2, 2021 2021/05/27 12:15:00 GlobeNewswire
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 June 4, 2021.
Advanced Ophthalmology Technologies Market to Witness Growth Acceleration by Top Key Players Johnson & Johnson, Novartis, Alimera Sciences, Teva Pharmaceutical, Bausch + Lomb, CooperVision 2021/05/19 06:49:23 Jumbo News
Global Advanced Ophthalmology Technologies Market size, share and CAGR Analysis 2021-2027 Advanced Ophthalmology Technologies Market report performs comprehensive Analysis about Global Market and tells about the market status in the forecast period. The report recognizes and analyses the growing trends along with major drivers, restraints, challenges and opportunities in the Advanced Ophthalmology Technologies industry. The []
2021 Global Retinal Disorders Drugs Market Is Booming by Leading Players| ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum 2021/05/13 03:57:54 Jumbo News
May13,2021 (Reports and Markets) Retinal Disorders Drugs Market is growing at a High CAGR during the forecast period 2021-2027. This report studies the Retinal Disorders Drugs market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific []
Alimera Sciences Inc. Shares Close the Week 47.9% Higher - Weekly Wrap 2021/03/12 22:30:00 Kwhen Finance
Alimera Sciences Inc. shares closed this week 47.9% higher than it did at the end of last week. The stock is currently up 164.0% year-to-date, up 156.1% over the past 12 months, and down 56.1% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $11.50 and as low as $7.44 this week.Shares closed 3% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 20.4% lower than the 10-day average and 13.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 663.5% The company's stock price performance over the past 12 months beats the peer average by 274.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Alimera Sciences will move its headquarters into the latest phase of a 135-acre Alpharetta project 2021/06/02 12:03:07 BusinessMag
Alimera maintains its headquarters in a 2-story building at 6120 Windward Parkway that was developed over 20 years ago.
Alimera Sciences, Inc. to Present at the Summer Solstice Best Ideas from the Buy Side Conference on June 2, 2021 2021/05/27 12:15:00 GlobeNewswire
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 June 4, 2021.
Advanced Ophthalmology Technologies Market to Witness Growth Acceleration by Top Key Players Johnson & Johnson, Novartis, Alimera Sciences, Teva Pharmaceutical, Bausch + Lomb, CooperVision 2021/05/19 06:49:23 Jumbo News
Global Advanced Ophthalmology Technologies Market size, share and CAGR Analysis 2021-2027 Advanced Ophthalmology Technologies Market report performs comprehensive Analysis about Global Market and tells about the market status in the forecast period. The report recognizes and analyses the growing trends along with major drivers, restraints, challenges and opportunities in the Advanced Ophthalmology Technologies industry. The []
2021 Global Retinal Disorders Drugs Market Is Booming by Leading Players| ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum 2021/05/13 03:57:54 Jumbo News
May13,2021 (Reports and Markets) Retinal Disorders Drugs Market is growing at a High CAGR during the forecast period 2021-2027. This report studies the Retinal Disorders Drugs market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific []
Alimera Sciences Inc. Shares Close the Week 47.9% Higher - Weekly Wrap 2021/03/12 22:30:00 Kwhen Finance
Alimera Sciences Inc. shares closed this week 47.9% higher than it did at the end of last week. The stock is currently up 164.0% year-to-date, up 156.1% over the past 12 months, and down 56.1% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $11.50 and as low as $7.44 this week.Shares closed 3% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 20.4% lower than the 10-day average and 13.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 663.5% The company's stock price performance over the past 12 months beats the peer average by 274.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.